506840548 08/27/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6887369

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ARON ERICKSON	01/31/2020
AMANDA STORJOHANN	01/31/2020
RICHARD NYGAARD	02/03/2020
RICHARD CUNNINGHAM	02/24/2020
KERRI CROSSEY	02/21/2020
MARIE EUGENIE MIGAUD	02/12/2020
PHILIP REDPATH	02/12/2020

RECEIVING PARTY DATA

Name:	CHROMADEX INC.	
Street Address: 10005 MUIRLANDS BLVD.		
City: IRVINE		
State/Country:	CALIFORNIA	
Postal Code:	92618	
Name:	THE QUEEN'S UNIVERSITY OF BELFAST	
Name: Street Address:	THE QUEEN'S UNIVERSITY OF BELFAST UNIVERSITY ROAD	
Street Address:	UNIVERSITY ROAD	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	17323789	

CORRESPONDENCE DATA

Fax Number: (312)884-7352

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3124661033

Email: patent@amintalati.com

Correspondent Name: AMIN TALATI WASSERMAN LLP

Address Line 1: 100 S. WACKER DRIVE

Address Line 2: **SUITE 2000**

REEL: 057308 FRAME: 0040 506840548

PATENT

Address Line 4: CHIC	CHICAGO, ILLINOIS 60606	
ATTORNEY DOCKET NUMBER:	CHROM-133-US-CON2	
NAME OF SUBMITTER:	GEORGE M. CARRERA, JR.	
SIGNATURE:	/George M. Carrera, Jr./	
DATE SIGNED:	08/27/2021	

Total Attachments: 7

source=executed Assignment - CROSSEY_CHROM133#page1.tif source=executed Assignment - CUNNINGHAM_CHROM133#page1.tif source=executed Assignment - ERICKSON_CHROM133#page1.tif source=executed Assignment - NYGAARD_CHROM133#page1.tif source=executed Assignment - REDPATH_CHROM133#page1.tif source=executed Assignment - STORJOHANN_CHROM133#page1.tif source=executed Assignment -MIGAUD_CHROM133#page1.tif

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Kerri Crossey – (hereinafter, the "Assignor") 306 Hillhead Road, Knockloughrim Magherafelt, Derry BT45 8QT UNITED KINGDOM

acknowledges the payment by and receipt from

The Queen's University of Belfast - (the "Assignee")
University Road
Belfast, Northern Ireland BT1 INN
UNITED KINGDOM

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworm testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

By:	ASSIGNOR Ki (1085ey	Accepted By:	ASSIGNEE - The Queen's University of Belfast
	Signature		Signature
	Kerri Crossey		Dermot Tierney, Intellectual Property Manager
	Printed Name 21 - FEBPUREY - 2020		Printed Name and Title
	Date	infi	Date 28 Feb 2020

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Richard Cunningham -- (hereinafter, the "Assignor") 25 Loughgall Road Portadown, Armagh BT62 4DB UNITED KINGDOM

acknowledges the payment by and receipt from

The Queen's University of Belfast -- (the "Assignee")
University Road
Belfast, Northern Ireland BT1 INN
UNITED KINGDOM

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

By:	ASSIGNOR L Signature	Accepted By:	ASSIGNEE - The Queen's University of Belfast
	Richard Cunningham Printed Name Richard Convolus		Dermot Tierney, Intellectual <u>Property Manager</u> Printed Name and Title
	Date 24/02/12/20	i of i	Date 28 Feb 2020

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Aron Erickson – (hereinafter, the "Assignor")
2209 Medford
Longmont, CO
80504 USA

acknowledges the payment by and receipt from

ChromaDex Inc. – (the "Assignee") 10005 Muirlands, Suite G Irvine, California 92618 USA

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

1 df 1

Ву:	ASSIGNOR Signature	Accepted By:	ASSIGNEE - ChromaDex, Inc. Signature
	Aron Erickson Printed Name 31 - Jan - 2020 Date		Mark Friedman, General Counsel & Secretary Printed Name and Title

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Richard Nygaard -- (hereinafter, the "Assignor") 3800 Pike Road, Apt. 16204 Longmont, CO 80503 USA

acknowledges the payment by and receipt from

ChromaDex Inc. — (the "Assignee") 10005 Muirlands, Suite G Irvine, California 92618 USA

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

ASSIGNOR	ASSIGNEE - ChromaDex, Inc.
By: 248	Accepted By:
Signature	Signature
Richard Nygaard	Mark Friedman, General Counsel & Secretary
Printed Name 03 Fe/s 2020	Printed Name and Title
Date	Date

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Philip Redpath — (hereinafter, the "Assignor") 55 Oakdene Park, Bleary Portadown, Armagh BT63 55B UNITED KINGDOM

acknowledges the payment by and receipt from

The Queen's University of Belfast - (the "Assignee")
University Road
Belfast, Northern Ireland BT1 1NN
UNITED KINGDOM

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

	ASSIGNOR		ASSIGNEE - The Queen's University of Belfas
8v:	141 1/4-	Accepted By:	
	Signature		Signature
	Philip Redpath		Dermot Tierney, Intellectual Property Manager
Print	Printed Name 1244 <i>F&B</i> 2020		Printed Name and Title
	Date		Date 28 Feb 2020
		i of i	

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Amanda Storjohann – (hereinafter, the "Assignor") 10110 Eaton Street Westminster, CO 80020 USA

acknowledges the payment by and receipt from

ChromaDex Inc. – (the "Assignee") 10005 Muirlands, Suite G Irvine, California 92618 USA

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Qunningham, Aron Erickson, Richard Nygaard, and Amanda Storiohann (the "Patent Application"); the Patent Application, any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provistonal Application(s).

By:

Amanda Storjohann

Printed Name

2020 31Jan

Date

ASSIGNEE - ChromaDex, Inc.

Accepted By:

Signature

Mark Friedman, General Counsel & Secretary

Printed Name and Title

21612020

1 df]1

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Marie Eugenie Migaud – (hereinafter, the "Assignor") 41 Banbridge Road Lurgan, Armagh BT66 7HG UNITED KINGDOM

acknowledges the payment by and receipt from

The Queen's University of Belfast – (the "Assignee")
University Road
Belfast, Northern Ireland BT1 INN
UNITED KINGDOM

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF

which is/are described and/or claimed in a Patent application for Letters Patent of the United States, Serial Number 15/809,753 filed on November 10, 2017, which claims benefit of U.S. Provisional applications 62/420,737 filed November 11, 2016 and 62/558,073 filed September 13, 2017, executed by the Assignor and naming as inventor(s) Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, and Amanda Storjohann (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

Bv:	ASSIGNOR	ASSIGNEE - The Queen's University of Belfast Accepted By:
293.	Signature	Signatúre
	Marie Eugenie Migaud Printed Name 12 February 2020	<u>Dermot Tierney, Intellectual Property Manager</u> Printed Name and Title
	Date	Date 28 Feb 2020

PATENT REEL: 057308 FRAME: 0048

RECORDED: 08/27/2021